These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

662 related items for PubMed ID: 18827614

  • 1. A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer.
    Ebi N, Semba H, Tokunaga SJ, Takayama K, Wataya H, Kuraki T, Yamamoto H, Akamine SJ, Okamoto I, Nakanishi Y, Lung Oncology Group in Kyushu, Japan.
    J Thorac Oncol; 2008 Oct; 3(10):1166-71. PubMed ID: 18827614
    [Abstract] [Full Text] [Related]

  • 2. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
    Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber DA, Johnson BE, Lynch TJ.
    J Clin Oncol; 2008 May 20; 26(15):2442-9. PubMed ID: 18458038
    [Abstract] [Full Text] [Related]

  • 3. Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study.
    Asami K, Koizumi T, Hirai K, Ameshima S, Tsukadaira A, Morozumi N, Morikawa A, Atagi S, Kawahara M.
    Clin Lung Cancer; 2011 Nov 20; 12(6):387-92. PubMed ID: 21729650
    [Abstract] [Full Text] [Related]

  • 4. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study.
    Maemondo M, Minegishi Y, Inoue A, Kobayashi K, Harada M, Okinaga S, Morikawa N, Oizumi S, Tanaka T, Isobe H, Kudoh S, Hagiwara K, Nukiwa T, Gemma A.
    J Thorac Oncol; 2012 Sep 20; 7(9):1417-22. PubMed ID: 22895139
    [Abstract] [Full Text] [Related]

  • 5. Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001.
    Ichihara E, Hotta K, Nogami N, Kuyama S, Kishino D, Fujii M, Kozuki T, Tabata M, Harada D, Chikamori K, Aoe K, Ueoka H, Hosokawa S, Bessho A, Hisamoto-Sato A, Kubo T, Oze I, Takigawa N, Tanimoto M, Kiura K.
    J Thorac Oncol; 2015 Mar 20; 10(3):486-91. PubMed ID: 25695221
    [Abstract] [Full Text] [Related]

  • 6. A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test.
    Choi MK, Hong JY, Chang WJ, Kim MJ, Kim SM, Jung HA, Do IG, Choi YL, Sun JM, Ahn JS, Park K, Ahn MJ.
    Cancer Chemother Pharmacol; 2015 Jun 20; 75(6):1229-36. PubMed ID: 25903122
    [Abstract] [Full Text] [Related]

  • 7. First-line gefitinib treatment for patients with advanced non-small cell lung cancer with poor performance status.
    Lee YJ, Kim HT, Han JY, Yun T, Lee GK, Kim HY, Sung JH, Lee JS.
    J Thorac Oncol; 2010 Mar 20; 5(3):361-8. PubMed ID: 20107420
    [Abstract] [Full Text] [Related]

  • 8. Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status.
    Okuma Y, Hosomi Y, Nagamata M, Yamada Y, Sekihara K, Kato K, Hishima T, Okamura T.
    Anticancer Res; 2013 Nov 20; 33(11):5057-64. PubMed ID: 24222150
    [Abstract] [Full Text] [Related]

  • 9. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
    Soria JC, Wu YL, Nakagawa K, Kim SW, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, Ponce S, Lee DH, Liu Y, Yoh K, Zhou JY, Shi X, Webster A, Jiang H, Mok TS.
    Lancet Oncol; 2015 Aug 20; 16(8):990-8. PubMed ID: 26159065
    [Abstract] [Full Text] [Related]

  • 10. A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
    Yoshioka H, Hotta K, Kiura K, Takigawa N, Hayashi H, Harita S, Kuyama S, Segawa Y, Kamei H, Umemura S, Bessho A, Tabata M, Tanimoto M, Okayama Lung Cancer Study Group.
    J Thorac Oncol; 2010 Jan 20; 5(1):99-104. PubMed ID: 19898258
    [Abstract] [Full Text] [Related]

  • 11. Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group.
    Agarwala A, Fisher W, Bruetman D, McClean J, Taber D, Titzer M, Juliar B, Yu M, Breen T, Einhorn LH, Hanna N.
    J Thorac Oncol; 2008 Apr 20; 3(4):374-9. PubMed ID: 18379355
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial.
    Spigel DR, Hainsworth JD, Burkett ER, Burris HA, Yardley DA, Thomas M, Jones SF, Dickson NR, Scullin DC, Bradof JE, Rubinsak JR, Brierre JE, Greco FA.
    Clin Lung Cancer; 2005 Sep 20; 7(2):127-32. PubMed ID: 16179100
    [Abstract] [Full Text] [Related]

  • 14. Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer.
    He C, Liu M, Zhou C, Zhang J, Ouyang M, Zhong N, Xu J.
    Int J Cancer; 2009 Nov 15; 125(10):2393-9. PubMed ID: 19530244
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer.
    Kimura H, Kasahara K, Shibata K, Sone T, Yoshimoto A, Kita T, Ichikawa Y, Waseda Y, Watanabe K, Shiarasaki H, Ishiura Y, Mizuguchi M, Nakatsumi Y, Kashii T, Kobayashi M, Kunitoh H, Tamura T, Nishio K, Fujimura M, Nakao S.
    J Thorac Oncol; 2006 Mar 15; 1(3):260-7. PubMed ID: 17409866
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations.
    Kuwako T, Imai H, Masuda T, Miura Y, Seki K, Yoshino R, Kaira K, Utsugi M, Shimizu K, Sunaga N, Tomizawa Y, Ishihara S, Ishizuka T, Mogi A, Hisada T, Minato K, Takise A, Saito R, Yamada M.
    Cancer Chemother Pharmacol; 2015 Oct 15; 76(4):761-9. PubMed ID: 26254024
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.